SURF-201の新興薬剤に関する洞察と市場予測：2032年

SURF-201は0.2%のベタメタゾンであり、Surface社が特許を有するクラリティビヒクルで溶液として製剤化されたユニークで強力なコルチコステロイドであり、現在使用されているコルチコステロイドと比較して、有効性と安全性の向上を目的としています。SURF-201は、米国で初めてベタメタゾンを利用した眼科治療薬であり、術後の痛みや炎症を治療する初めての防腐剤フリーの単位用量治療薬です。最近、同社は第II相臨床試験を完了しました。2021年1月、Surface OphthalmicsはSURF-201の第II相臨床試験から良好なトップライン結果を発表しました。

今後数年間で、急性眼痛の市場シナリオは、世界中の広範な調査と医療費の増加により変化することが予想されます。各社は、病状を治療／改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、SURF-201の優位性に影響を与える可能性のある機会を模索しています。急性眼痛に対する他の新興製品がSURF-201に厳しい市場競争を与えることが予想され、近い将来、後発の新興治療薬の発売が市場に大きな影響を与えるとみられています。

当レポートでは、主要8ヶ国におけるSURF-201市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性眼痛に対するSURF-201の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 SURF-201市場評価

• 急性眼痛におけるSURF-201の市場展望
• 主要8ヶ国市場分析
  • 主要8ヶ国市場における急性眼痛に対するSURF-201の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • カナダ
  • 韓国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: SURF-201, Clinical Trial Description, 2023
• Table 2: SURF-201, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: SURF-201 Market Size in the 8MM, in USD million (2019-2032)
• Table 6: SURF-201 Market Size in the US, in USD million (2019-2032)
• Table 7: SURF-201 Market Size in Germany, in USD million (2019-2032)
• Table 8: SURF-201 Market Size in France, in USD million (2019-2032)
• Table 9: SURF-201 Market Size in Italy, in USD million (2019-2032)
• Table 10: SURF-201 Market Size in Spain, in USD million (2019-2032)
• Table 11: SURF-201 Market Size in the UK, in USD million (2019-2032)
• Table 12: SURF-201 Market Size in Canada, in USD million (2019-2032)
• Table 13: SURF-201 Market Size in South Korea, in USD million (2019-2032)

List of Figures

• Figure 1: SURF-201 Market Size in the 8MM, USD million (2019-2032)
• Figure 2: SURF-201 Market Size in the United States, USD million (2019-2032)
• Figure 3: SURF-201 Market Size in Germany, USD million (2019-2032)
• Figure 4: SURF-201 Market Size in France, USD million (2019-2032)
• Figure 5: SURF-201 Market Size in Italy, USD million (2019-2032)
• Figure 6: SURF-201 Market Size in Spain, USD million (2019-2032)
• Figure 7: SURF-201 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: SURF-201 Market Size in Canada, USD million (2019-2032)
• Figure 9: SURF-201 Market Size in South Korea, USD million (2019-2032)

“"SURF-201 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SURF-201 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the SURF-201 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SURF-201 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SURF-201 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

SURF-201 is 0.2% betamethasone, a unique and potent corticosteroid formulated as a solution in Surface's patented Klarity vehicle and intended to provide improved efficacy and safety compared to currently used corticosteroids. SURF-201 marks the first ophthalmic therapeutic in the United States to utilize betamethasone and the first preservative-free unit dose therapy for treating postoperative pain and inflammation. Recently, a Phase II clinical study was completed by the company. In January 2021, Surface Ophthalmics announced positive topline results from the Phase II trial for SURF-201.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SURF-201 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
• Elaborated details on SURF-201 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SURF-201 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
• The report also covers the patents information with expiry timeline around SURF-201.
• The report contains forecasted sales of SURF-201 for acute ocular pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
• The report also features the SWOT analysis with analyst views for SURF-201 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SURF-201 Analytical Perspective by DelveInsight

In-depth SURF-201 Market Assessment

This report provides a detailed market assessment of SURF-201 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

SURF-201 Clinical Assessment

The report provides the clinical trials information of SURF-201 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SURF-201 dominance.
• Other emerging products for acute ocular pain are expected to give tough market competition to SURF-201 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SURF-201 in acute ocular pain.
• Our in-depth analysis of the forecasted sales data of SURF-201 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SURF-201 in acute ocular pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of SURF-201?
• What is the clinical trial status of the study related to SURF-201 in acute ocular pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SURF-201 development?
• What are the key designations that have been granted to SURF-201 for acute ocular pain?
• What is the forecasted market scenario of SURF-201 for acute ocular pain?
• What are the forecasted sales of SURF-201 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
• What are the other emerging products available and how are these giving competition to SURF-201 for acute ocular pain?
• Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?

Table of Contents

1. Report Introduction

2. SURF-201 Overview in Acute ocular pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SURF-201 Market Assessment

• 5.1. Market Outlook of SURF-201 in Acute ocular pain
• 5.2. 8MM Analysis
  • 5.2.1. Market Size of SURF-201 in the 8MM for Acute ocular pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SURF-201 in the United States for Acute ocular pain
  • 5.3.2. Market Size of SURF-201 in Germany for Acute ocular pain
  • 5.3.3. Market Size of SURF-201 in France for Acute ocular pain
  • 5.3.4. Market Size of SURF-201 in Italy for Acute ocular pain
  • 5.3.5. Market Size of SURF-201 in Spain for Acute ocular pain
  • 5.3.6. Market Size of SURF-201 in the United Kingdom for Acute ocular pain
  • 5.3.7. Market Size of SURF-201 in Canada for Acute ocular pain
  • 5.3.8. Market Size of SURF-201 in South Korea for Acute ocular pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options